Actionable strategies to maximise opportunity and mitigate risk
With over 30 years of industry experience, we support our clients with strategic advice and full end-to-end process management capabilities to achieve the best outcome from their strategic transactions.
Using internal therapeutic expertise coupled with targeted data analytics, PharmaVentures works in collaboration with clients to develop actionable strategies to maximise their opportunity and mitigate risk.
Expertise and knowledge
- Therapeutic area expertise particularly in Oncology, CVMD, CNS, Respiratory, Immunology and Orphan/Rare Diseases
- Market understanding & assessment including extensive experience in Global, Regional and Country-specific projects; especially across the US, EU5 and Asia-Pacific markets. Deep understanding of the specific clinical and commercial market dynamics, trends, drivers and challenges
- Asset strategy development including clinical and commercial processes to understand and validate the opportunity and support the development of strategic decisions
- Competitor differentiation overview of the market landscape and strategy development to enable successful positioning of the client’s assets
Our Case Studies
An early stage biotechnology company was seeking to develop a global/regional strategy for the commercialisation of their Phase I compound to maximise the value to the company over the potential life cycle of the product.
A mid-sized life sciences manufacturing company with new cell lines developed a novel pipeline and they sought the partnership of a global or several regional pharmaceutical companies with strong competencies in clinical development and marketing in the focus therapy areas.
A major pharmaceutical company was seeking mid market growth products for emerging markets. PharmaVentures was chosen because its knowledge of the global pharmaceutical market, access to proprietary data resources as well its transaction experience in effectively acquiring these on behalf of clients.
How can we help you?
Strategy needs insight. Talk to us to fully explore all opportunities within the life sciences industry.
Assess assets and decide on opportunity prioritisation
Search, find and prioritise
Forecasting/ financial modelling
Key opinion leader identification and analysis
All FCA regulated activities are delivered through PharmaVentures Capital Limited, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Limited is a wholly owned subsidiary of Pharma Ventures Ltd. Past performance is not a guarantee of future performance. Information contained herein is for illustrative purposes only and should not be relied upon.
Our White Papers
In the last few years, pharmaceutical companies have become increasingly interested in biomarkers and their incorporation into company drug development programmes and use as companion tests for targeted therapeutics.
Policy-driven changes in healthcare spending and the growing significance of generic competition are acting in tandem to force pharma manufacturing companies to adopt more cost-effective manufacturing strategies resulting in an upsurge in the level of M&A activity.